Menu
Recruiting NCT05183165

Description of the Copper Concentration in Breast Milk in Women Treated for Wilson's Disease

No phase Interventional Wilson's Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Patients with Wilson's disease declaring pregnancy,.
Who it may be relevant to
Registry conditions: Wilson's Disease. Basic parameters: from 18 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Wilson's disease is a rare genetic disease, affecting less than 1,500 people in France. The transmission is autosomal recessive linked to an anomaly of the ATP7B gene on chromosome.This gene codes for an ATPase-type transmembrane protein involved in the transport of copper through the cell plasma member.This gene codes for an ATPase-type transmembrane protein involved in the transport of copper through the cell plasma member. If there is no mutation, this ATPase incorporates copper into apo-ceruloplasmin to be released into the blood serum. The mutation of the ATP7B gene results in a defective biliary excretion of copper, leading to its accumulation in the liver, but also in other organs such as the eye or the brain. Advances in treatment have dramatically changed the prognosis for Wilson's disease, making the desire for pregnancy more confident. The consensus is to maintain treatment during pregnancy, reducing the dosage to limit teratogenicity as well as the risk of fetal copper deficiency.The mammary gland is the primary site of copper metabolism in lactation, and ATPase 7B is the primary effector. It has been shown in a mouse model of Wilson's disease (ATP7B - / - mouse) with treatment, that mothers accumulate copper in the liver but also in the mammary gland. However, a recent study showed that the copper level in breast milk was normal in 18 Wilsonian patients treated with D-penicillamine, trientine salts or zinc salts, suggesting that breastfeeding is possible in these patients without risk to the development of the infants.The problem of breastfeeding newborns for patients with Wilson's disease is therefore associated with a risk of copper deficiency in the newborn due to insufficiently rich breast milk in copper due to drugs. In addition, the passage into breast milk of treatments is not sufficiently known. These factors make breastfeeding not currently recommended for Wilsonian mothers,However, many patients wish to breastfeed and some of them breastfeed their newborns despite the risk of breastfeeding

Interventions

  • Other Patients with Wilson's disease declaring pregnancy,
    Blood and urine biological assessment Dietary assessment

Primary outcome measures

  • Concentration of total copper (bound and free) in µmol / L in a sample of breast milk [Time frame: 1 day ± 24 hours after childbirth]

Eligibility criteria

Criteria for inclusion :

  • Patient aged 18 years or over.
  • Wilson's disease fulfilling the criteria for the Leipzig score
  • Pregnancy in progress whatever the term.
  • Express consent to participate in the study.
  • Affiliate or beneficiary of a social security system.

Criteria for non-inclusion :

  • Liver transplant patient
  • No affiliation to Social Security system
  • VuInability to give free and informed consent
  • Patient benefiting from a legal protection measure

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Other

Study locations

France · 1 center
  • Fondation Adolphe de Rothschild — Paris

Identifiers

NCT: NCT05183165 · AOA_2021_28

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗